This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Universitéde Montreal. Active years: 2006-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
7 out of 3,745 
5 out of 189 
Years Active: 2006-2024
Title: **Pancras C. Wong: Innovator in Platelet Aggregation Inhibition**
Introduction
Pancras C. Wong is a distinguished inventor based in Plainsboro, NJ, recognized for his significant contributions to the field of medicinal chemistry. With a total of seven patents to his name, Wong's innovative work focuses primarily on developing compounds that inhibit platelet aggregation, thereby providing therapeutic options for thromboembolic disorders.
Latest Patents
Wong's most recent patents include groundbreaking inventions centered around imidazothiadiazole and imidazopyrazine derivatives. These compounds serve as protease activated receptor 4 (PAR4) inhibitors critical in treating platelet aggregation. The inventions disclose thiazole compounds of specific formulas, which encompass various stereoisomers, tautomers, pharmaceutically acceptable salts, prodrug esters, or solvate forms. These compounds have potent inhibitory effects on platelet aggregation, paving the way for new medicaments aimed at treating or preventing conditions associated with thromboembolic disorders.
Career Highlights
Throughout his career, Wong has garnered invaluable experience working with notable organizations, including Bristol-Myers Squibb Company and the Université de Montréal. His expertise in medicinal chemistry and innovative approach to drug design have positioned him as a key figure in developing novel therapeutic agents.
Collaborations
Wong has collaborated with leading professionals in the field, such as Edward H. Ruediger and Julia Guy. These partnerships have further enhanced his research efforts and contributed to the advancement of science in platelet aggregation inhibition.
Conclusion
Pancras C. Wong exemplifies the spirit of innovation within the medical and pharmaceutical fields. His extensive patent portfolio and collaborative efforts highlight his commitment to enhancing healthcare through significant scientific contributions. As Wong continues to explore new avenues for therapeutic development, his work stands to impact the treatment of thromboembolic disorders profoundly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile